Tyr529
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr529  -  RSK2 (human)

Site Information
TITKTVEyLHAQGVV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 464205

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 4 ) , mass spectrometry ( 4 , 5 , 6 ) , mutation of modification site ( 3 , 4 ) , phospho-antibody ( 1 , 3 , 4 ) , western blotting ( 1 , 3 , 4 )
Disease tissue studied:
breast cancer ( 1 ) , breast adenocarcinoma ( 1 ) , myeloproliferative disorder ( 4 ) , multiple myeloma ( 4 )
Relevant cell line - cell type - tissue:
293T (epithelial) ( 3 ) , BaF3 ('B lymphocyte, precursor') [FGFR3 (human)] ( 4 ) , CCLP1 (hepatic) ( 4 ) , COS (fibroblast) ( 3 ) , KMS-11 (B lymphocyte) ( 4 ) , KMS-11 (B lymphocyte) [FGFR3 (mouse)] ( 4 ) , MCF10A1 (epithelial) ( 1 ) , MDA-MB-361 (breast cell) ( 1 ) , NCI-H929 (B lymphocyte) ( 4 ) , OPM-1 (B lymphocyte) ( 4 ) , RPMI-8226 (plasma cell) ( 4 ) , SKBr3 (breast cell) ( 1 ) , U266 (plasma cell) ( 4 )

Upstream Regulation
Putative in vivo kinases:
FGFR3 (human) ( 4 ) , Fyn (human) ( 3 ) , Src (human) ( 3 )
Kinases, in vitro:
ERK2 (human) ( 4 ) , FGFR3 (human) ( 3 , 4 ) , Fyn (human) ( 3 ) , Src (human) ( 3 )
Treatments:
EGF ( 3 ) , FGF2 ( 1 ) , PP2 ( 3 ) , SB202190 ( 1 ) , SU6656 ( 1 ) , U0126 ( 1 , 3 )

Downstream Regulation
Effects of modification on RSK2:
molecular association, regulation ( 3 , 4 )
Effects of modification on biological processes:
apoptosis, altered ( 4 ) , cell growth, induced ( 1 ) , cell motility, induced ( 1 )
Induce interaction with:
ERK1 (human) ( 3 ) , ERK2 (human) ( 3 ) , FGFR3 (human) ( 4 )

References 

1

Czaplinska D, et al. (2014) Phosphorylation of RSK2 at Tyr529 by FGFR2-p38 enhances human mammary epithelial cells migration. Biochim Biophys Acta 1843, 2461-70
25014166   Curated Info

2

Shimura Y, et al. (2012) RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Mol Cancer Ther 11, 2600-9
23012246   Curated Info

3

Kang S, et al. (2008) Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. J Biol Chem 283, 4652-7
18156174   Curated Info

4

Kang S, et al. (2007) FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12, 201-14
17785202   Curated Info

5

Gu T (2007) CST Curation Set: 2464; Year: 2007; Biosample/Treatment: cell line, RSK2-7/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Gu T (2007) CST Curation Set: 2465; Year: 2007; Biosample/Treatment: cell line, RSK2-8/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info